SMC endorses Alexion’s Ultomiris
Committee also accepted Braftovi combination, Ledaga and Zejula for use by NHS Scotland in May decisions
Read More
Tag: Legada
- GSK wins US approval for ROS1 lung cancer therapy
- Lundbeck secures FDA Fast Track for narcolepsy drug
- R1 Therapeutics begins global phase 2b trial of AP306 for hyperphosphatemia
- Mission Therapeutics divests MTX652 to Dimerix in deal worth up to $292 million
- Nouscom to present re‑treatment data in Lynch Syndrome at ESMO 2026
